A 26-week Treatment, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 (50 microg o.d.) in Patients With Chronic Obstructive Pulmonary Disease
Latest Information Update: 12 Nov 2019
At a glance
- Drugs Glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms GLOW-7
- Sponsors Novartis; Novartis Pharmaceuticals
- 07 Mar 2013 New source identified and integrated (Clinical Trials Registry - India; CTRI2012-08-002907).
- 10 Apr 2012 New trial record